

Janice L. Krieger, Ph.D.

Disclosure of Commercial Interest

It is the policy of the Prevent Cancer Foundation and the Nurse Practitioners in Women's Health that the education presented at CE-certified activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the Prevent Cancer Foundation provides information that faculty have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this educational activity.

There will not be any off-label and/or investigational use of products discussed within the content at any of the presentations at this conference.

Developing Personalized Colorectal Cancer Screening Messages for Rural and Minority Residents in Florida

Dr. Janice Krieger has indicated she has no relevant financial relationships within the past 12 months.



IS THE FUTURE OF PREVENTION VIRTUAL?

Developing personalized colorectal cancer screening messages for rural and minority residents in Florida

Dialogue for Action April 25, 2019

Janice Krieger, PhD University of Florida

Director, STEM Translational Communication Center Professor, Advertising & Health Outcomes & Biomedical Informatics Program Co-Director, Cancer Population Sciences, UF Cancer Center








Making the science of health more...

ACCESSIBLE

UNDERSTANDABLE

USABLE

HEALTH INEQUITIES IN FLORIDA: COLORECTAL CANCER



COMMUNICATION CHALLENGES

Changes in Screening Guidelines



"Good news.

Your cholesterol has stayed the same, but the research findings have changed."

PRECISION MESSAGING







RIGHT PERSON



RIGHT PLACE



RIGHT TIME

USING PRECISION MESSAGES TO ADDRESS RURAL HEALTH





- Designing and evaluating rural-centric health decision-making interventions
- Mindful of both:
 - rural "place"
 - cultural "space"

PRECISION MESSAGES TO ADDRESS SOCIAL VULNERABILITY

SOCIOECONOMIC STATUS


(Below Poverty, Unemployed, No high school diploma)

HOUSEHOLD COMPOSITION & DISABILITY

(Aged 65 and Older, Aged 17 and Younger, Civilian with a Disability, Single-Parent Households)

HOUSING & TRANSPORTATION

(Multi-Unit Structures, Mobile Homes, Crowding, No Vehicle, Group Quarters)







Colon Cancer Screening Kit

What is a FIT test?

The easiest way to screen for colon cancer is a **Fecal Immunochemical Test** (FIT). IT is used to find microscopic amounts of blood in stool, which may be (but is not always) an early sign of colon cancer. It is an important part of colon cancer prevention.

When colon cancer is detected through regular FIT screening, the cancer is more likely at a curable stage. If your FIT results come back abnormal, your doctor will schedule a colonoscopy to find out why.

Included in your kit:









Important notes



Remove any deodorizers / fresheners / cleaners from the toilet bowl and flush the toilet twice prior to performing the test. If there is a rust ring in your toilet remove the ring or use an alternate toilet.




Do not use the kit if you are menstruating or have hemorrhoids that are bleeding.

Instructions on back



Quartions?







FIT **TESTING**

- Multi-level intervention to promote CRC screening
- Patients participate in "virtual" appointment
- Fecal immunochemical testing (FIT)
- Built in reminder system


VIRTUAL HUMAN TECHNOLOGY



BENEFITS

- Customizable messages
- Reduces embarrassment
- Demonstrates correct stool collection

AGILE INTERVENTION DEVELOPMENT



COMMUNITY ADVISORY **BOARD**



AIM 1

Formative Research

8
INITIAL FOCUS
GROUPS

16

FOLLOW-UP FOCUS GROUPS

14

COMMUNITY MEMBERS

50

THINK ALOUD INTERVIEWS





OF ALEX





















EVOLUTION OF **ALEX**









Aim 2: Clinical Implementation Recruitment



PARTICIPANTS

Patients (50-73)

Eligibility: data warehouse criteria + chart review



Low risk

Outside CRC screening guidelines



Patient portal + research registry

Clinics

Aim 2: Clinical Implementation Protocol



Randomized to message condition

Track patients screening behavior over 6 mos.

Non-responders enrolled in Phase 2



Rerandomized to message condition

Track screening over 6 mos.

Patients who screen advance To Phase 3




Follow patients longitudinally

Booster intervention messages

Determine which message elements are most effective

VIRTUAL HUMAN **EXAMPLE**



FUTURE **DIRECTIONS**







ACKNOWLEDGEMENTS

1R01CA207689-01A1

Co-Investigators (Ben Lok, Eric Laber, Peter Carek, Francois Modave, Marie Davidian, Thom George, Folake Odedina), Community Advisory Board Members, Lauren Griffin, Ken Stokes, Miriam Buhr, Pedro Ylsastigui, Melissa Vilaro, Danyell Wilson, Gigi Lapori, Tanja Magoc, Jordan Neil, Alyssa Jaisle, Mohan Zalake, Fatemah Tavassoli.



